1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 9 areas
0
News (30d)
Quiet
ArQule, Inc., a wholly owned subsidiary of Merck Sharp & Dohme, LLC is a company with 1 orphan drug designation across 3 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| B-cell chronic lymphocytic leukemia | nemtabrutinib | Des.TrialAppr. |
| T-cell prolymphocytic leukemia | nemtabrutinib | Des.TrialAppr. |
| chronic lymphocytic leukemia/small lymphocytic lymphoma | nemtabrutinib | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio